Gland Pharma Ltd — Tobramycin Exporter Profile
Indian Pharmaceutical Exporter · #4 for Tobramycin · $1.8M export value · DGFT Verified
Gland Pharma Ltd is the #4 Indian exporter of Tobramycin with $1.8M in export value and 35 verified shipments. Gland Pharma Ltd holds a 4.5% market share in Tobramycin exports across 2 countries.
Gland Pharma Ltd — Tobramycin Export Profile: Buyers & Destinations
Where Does Gland Pharma Ltd Export Tobramycin?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $2.0M | 44 | 83.6% |
| CANADA | $350.0K | 7 | 14.4% |
| UNITED STATES OF AMERICA | $50.0K | 1 | 2.1% |
Gland Pharma Ltd exports Tobramycin to 3 countries. The largest destination is UNITED STATES accounting for 83.6% of Gland Pharma Ltd's Tobramycin shipments, followed by CANADA (14.4%) and UNITED STATES OF AMERICA (2.1%). These destinations reflect Gland Pharma Ltd's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Tobramycin from Gland Pharma Ltd?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| EVERSANA LIFE SCIENCE SERVICES | UNITED STATES | $1.6M | 33 |
| STERIMAX INC | CANADA | $350.0K | 7 |
| INTEGRATED COMMERCIALIZATION | UNITED STATES | $222.4K | 6 |
| NORTHSTAR DISTIBUTION CENTRE | UNITED STATES | $100.0K | 2 |
| RAINBOW GOLD, INC | UNITED STATES | $86.2K | 3 |
| XIROMED, LLC, | UNITED STATES | $50.0K | 1 |
Gland Pharma Ltd supplies Tobramycin to 6 buyers globally. The largest buyer is EVERSANA LIFE SCIENCE SERVICES (UNITED STATES), followed by STERIMAX INC (CANADA) and INTEGRATED COMMERCIALIZATION (UNITED STATES). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Tobramycin Export Value and How Much Does Gland Pharma Ltd Contribute?
India exported $20.8M worth of Tobramycin through 2,676 shipments from 283 suppliers to 134 countries, serving 580 buyers globally. Gland Pharma Ltd contributes $1.8M to this total, accounting for 4.5% of India's Tobramycin exports. Gland Pharma Ltd ships Tobramycin to 3 countries through 6 buyers.
What Is the Average Shipment Value for Gland Pharma Ltd's Tobramycin Exports?
Gland Pharma Ltd's average Tobramycin shipment value is $50.0K per consignment, based on 35 shipments totaling $1.8M. The largest destination is UNITED STATES (83.6% of Gland Pharma Ltd's Tobramycin exports).
How Does Gland Pharma Ltd Compare to Other Indian Tobramycin Exporters?
Gland Pharma Ltd ranks #4 among 283 Indian Tobramycin exporters with a 4.5% market share. The top 3 exporters are MANKIND PHARMA LIMITED ($3.9M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($3.9M), SENTISS PHARMA PRIVATE LIMITED ($3.0M). Gland Pharma Ltd processed 35 shipments to 2 destination countries.
What Tobramycin Formulations Does Gland Pharma Ltd Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| TOBRAMYCIN FOR INJECTION USP 1.2GRAM PERVIAL, 50ML VIAL | $380.5K | 8 |
| TOBRAMYCIN FOR INJECTION USP 1.2G/VIAL, | $300.0K | 6 |
| TOBRAMYCIN FOR INJECTION USP 1.2GRAM PERVIAL 50ML VIAL | $300.0K | 6 |
| TOBRAMYCIN FOR INJECTION USP 1.2GRAM PERVIAL,50ML VIAL | $224.6K | 5 |
| TOBRAMYCIN FOR INJECTION USP 1.2G/VIAL | $150.5K | 4 |
| TOBRAMYCIN FOR INJECTION USP 1.2 GRAM PE | $150.0K | 3 |
| TOBRAMYCIN INJECTION USP 80MG/2ML (40MG/ML) | $100.0K | 2 |
| TOBRAMYCIN FOR INJECTION USP 1.2GRAM PERVIAL,50ML VIALNOS | $100.0K | 2 |
| TOBRAMYCIN FOR INJECTION USP 1.2 GRAM PER VIAL,50ML VIAL | $100.0K | 2 |
| TOBRAMYCIN FOR INJECTION USP 1 2GRAM PERVIAL 50ML VIAL | $100.0K | 2 |
Gland Pharma Ltd exports 19 distinct Tobramycin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is TOBRAMYCIN FOR INJECTION USP 1.2GRAM PERVIAL, 50ML VIAL with 8 shipments worth $380.5K.
Regulatory Requirements: Exporting Tobramycin to Key Markets
What Gland Pharma Ltd must comply with to export Tobramycin to its top destination countries
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Canada — HC
Approval Process
ANDS (Abbreviated New Drug Submission) referencing Canadian Reference Product. Comparative bioavailability study required.
Timeline: 12–18 months
GMP & Export Requirements
Health Canada GMP (GUI-0001); Drug Establishment Licence (DEL) inspection
Drug Identification Number (DIN) for each product; Certificate of Pharmaceutical Product from CDSCO
Note: Subject to Good Import Practices and annual C.01.014.6 review.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Gland Pharma Ltd Compare to Nearest Tobramycin Exporters?
Exporters ranked immediately above and below #4 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 3 | SENTISS PHARMA PRIVATE LIMITED | $3.0M | 60 | 1 | $50.0K |
| 5 | MYLAN LABORATORIES LIMITED | $2.3M | 45 | 2 | $50.0K |
| 4 | GLAND PHARMA LTD ★ | $1.8M | 35 | 2 | $50.0K |
| 7 | SOMERSET THERAPEUTICS LIMITED | $1.5M | 62 | 1 | $24.8K |
| 6 | GLAND PHARMA LIMITED | $850.0K | 17 | 2 | $50.0K |
Gland Pharma Ltd ranks #4 among 283 Indian Tobramycin exporters. Average shipment value of $50.0K compared to the market average of $73.4K. The closest competitors by value are SENTISS PHARMA PRIVATE LIMITED and MYLAN LABORATORIES LIMITED.
Which Indian Ports Ship Tobramycin Exports?
| Port | Shipments | % Share |
|---|---|---|
| DELHI AIR CARGO ACC (INDEL4) | 454 | 17.0% |
| SAHAR AIR CARGO ACC (INBOM4) | 329 | 12.3% |
| DELHI AIR | 316 | 11.8% |
| SAHAR AIR | 298 | 11.1% |
| NHAVA SHEVA SEA (INNSA1) | 93 | 3.5% |
| CHENNAI AIR CARGO ACC (INMAA4) | 88 | 3.3% |
| Delhi Air | 86 | 3.2% |
| Bombay Air | 79 | 3.0% |
Market Intelligence
Latest developments and market context
Detailed market intelligence for Tobramycin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Tobramycin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Gland Pharma Ltd matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 52 individual customs records matching Gland Pharma Ltd exporting Tobramycin, covering 19 formulations to 3 countries via 6 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 134+ countries, 580+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Tobramycin Export Data from Gland Pharma Ltd
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Gland Pharma Ltd's Tobramycin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Gland Pharma Ltd
Company Profile
0 products · $0 total trade · 0 categories
Tobramycin Stats
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Gland Pharma Ltd.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Tobramycin. For current shipment-level data, contact TransData Nexus.